Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
oxaliplatin + irinotecan
- Development stage
- Phase 3
- Lead developer
- Sanofi
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Oxaliplatin and irinotecan are both small molecule chemotherapy agents commonly used in combination regimens for the treatment of metastatic colorectal cancer and other solid tumors. Oxaliplatin is a third-generation platinum-based compound that exerts its cytotoxic effect primarily through DNA crosslinking, leading to inhibition of DNA replication and transcription, which results in cell death. Irinotecan is a topoisomerase I inhibitor that prevents the religation of single-strand breaks induced during DNA replication, causing double-strand breaks and apoptosis. The combination exploits complementary mechanisms to enhance antitumor activity. Both drugs are cell-cycle nonspecific but have distinct toxicity profiles; oxaliplatin is associated with neuropathy while irinotecan can cause diarrhea and myelosuppression[2][4][6].
- Other names
- oxaliplatin + irinotecan
02
Targets
DNATOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on oxaliplatin + irinotecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on oxaliplatin + irinotecan.